CVS Health Corporation $CVS Shares Purchased by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC grew its stake in shares of CVS Health Corporation (NYSE:CVS) by 6,039.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,008 shares of the pharmacy operator’s stock after buying an additional 9,845 shares during the quarter. Elevated Capital Advisors LLC’s holdings in CVS Health were worth $719,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in CVS. Swiss RE Ltd. acquired a new position in shares of CVS Health during the fourth quarter valued at approximately $26,000. Sankala Group LLC acquired a new stake in CVS Health in the fourth quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its stake in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. bought a new position in CVS Health during the 4th quarter valued at $28,000. Finally, Ares Financial Consulting LLC acquired a new position in shares of CVS Health during the 4th quarter valued at $29,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health declared a quarterly dividend of $0.665 per share, reinforcing its shareholder-return policy and signaling management confidence in cash generation. CVS Health declares quarterly dividend
• Positive Sentiment: Coverage around CVS highlighted the company as a likely beneficiary of managed-care consolidation, with commentary that Aetna is handling medical costs and that CVS is well positioned as Walgreens weakens. Cramer’s Stop Trading: CVS Health
• Neutral Sentiment: A CVS executive, Ali Keshavarz, was appointed to the board of Choice Hotels; this is notable for the executive’s profile but does not appear to have a direct operational impact on CVS. Choice Hotels (CHH) Appoints CVS Data Chief To Board As Index Changes Hit
• Negative Sentiment: CVS and Omnicare agreed to a $440 million settlement with the U.S. Department of Justice to resolve improper billing allegations, which creates a large one-time legal cost and keeps regulatory pressure on the company. CVS, Omnicare ink $440M deal with DoJ to resolve improper billing case
• Negative Sentiment: CVS also settled a separate $36.5 million case tied to false Medicaid insulin claims, adding to the legal overhang and reinforcing concerns about compliance risks. CVS settles for $36.5M over false Medicaid insulin claims, Minnesota recovers $400K

Analysts Set New Price Targets

CVS has been the topic of a number of research reports. Argus boosted their price objective on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Royal Bank Of Canada lifted their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday. Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. TD Cowen lifted their price objective on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Barclays increased their target price on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Twenty-one investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $102.84.

CVS Health Trading Up 1.3%

Shares of NYSE CVS opened at $104.15 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $106.15. The company has a market cap of $132.88 billion, a price-to-earnings ratio of 45.88, a P/E/G ratio of 1.01 and a beta of 0.61. The business has a fifty day simple moving average of $96.91 and a 200-day simple moving average of $84.17.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Insider Buying and Selling

In related news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. 0.85% of the stock is owned by company insiders.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.